title: Immunogenic cell death and cross-priming are reaching the clinical immunotherapy arena.
authors.affiliation: Centro de Investigación Médica Aplicada, Clínica Universitaria and School of Medicine, University of Navarra, Pamplona, Spain. imelero@unav.es
authors.forename: Ignacio
authors.initials: I
authors.lastname: Melero
authors.forename: Ainhoa
authors.initials: A
authors.lastname: Arina
authors.forename: Oihana
authors.initials: O
authors.lastname: Murillo
authors.forename: Juan
authors.initials: J
authors.lastname: Dubrot
authors.forename: Carlos
authors.initials: C
authors.lastname: Alfaro
authors.forename: Jose L
authors.initials: JL
authors.lastname: Pérez-Gracia
authors.forename: Maurizio
authors.initials: M
authors.lastname: Bendandi
authors.forename: Sandra
authors.initials: S
authors.lastname: Hervás-Stubbs
mesh_terms: D000818:Animals; D017209:Apoptosis / Q000276:immunology; D003713:Dendritic Cells / Q000166:cytology / Q000276:immunology / Q000637:transplantation*; D016219:Immunotherapy, Adoptive; D051379:Mice; D008954:Models, Biological; D009374:Neoplasms, Experimental / Q000276:immunology / Q000628:therapy*